Matinas Biopharma Holdings Inc., a Bedminster, N.J.-based company developing an omega-3 fatty acid-based therapy for cardiovascular and metabolic conditions called MAT9001, gained approval to move from the OTC Pink market to the OTC venture stage market, OTCQB.